Low Viscosity Active Delivery: Penetration Enhancer Selection & Efficacy Data

Overview #

pH is not just a stability parameter in low-viscosity actives. It is the primary delivery lever — and most brands don’t realize that until we’re already three batches in. Toners, essences, and treatment waters sit in a format that looks deceptively simple: mostly water, light texture, fast absorption. What’s actually happening at the skin barrier level is more complex than most moisturizer formulations we run. Getting penetration enhancer selection right at this viscosity range is where the real formulation work lives.

How We Read a Brief for This Format #

When a brand partner comes to us with a toner or essence brief, the first question we ask is: what’s the primary active, and what’s the target skin depth? Those two answers determine almost everything else — pH window, enhancer class, preservative strategy, and packaging.

Most briefs we receive say something like “brightening essence with niacinamide and vitamin C.” That combination immediately flags a pH conflict. Niacinamide is stable and effective at pH 5.5–7.0. Ascorbic acid needs pH below 3.5 to remain active. Put them together without thinking and you get niacinamide hydrolysis to nicotinic acid — the compound responsible for flushing — and an ascorbic acid that’s already oxidizing before the consumer opens the bottle. We push back on this brief almost every time.

For penetration enhancement specifically, the brief intake question we care about most is: are you targeting the stratum corneum lipid matrix, the intercellular pathway, or transappendageal delivery? Each pathway responds to a different enhancer class. Brands rarely know the answer. That’s fine — it’s our job to translate the consumer benefit claim into a delivery mechanism.

The enhancer classes we work with most in this format:

• Chemical penetration enhancers (CPEs): ethanol (5–20%), propylene glycol (5–15%), butylene glycol (3–10%), oleic acid (0.5–5%)
• Surfactant-based: polysorbate 20 at low levels (0.1–0.5%), sodium laureth sulfate avoided in leave-on
• Terpene-derived: menthol, limonene — effective but fragrance-load constrained
• Vesicular systems: liposomes, niosomes, transfersomes — encapsulation adds cost and complexity

The choice is never purely technical. It’s always a cost-and-performance trade-off.

Penetration Enhancer Selection: The Parameters That Actually Matter #

Ethanol is the workhorse. At 10–15% in a toner base, it disrupts stratum corneum lipid ordering, increases fluidity, and drives small hydrophilic molecules across the barrier faster than almost anything else at this price point. The sensory profile is clean, evaporation is fast, and it contributes to preservation. The problem: at concentrations above 20%, you start seeing barrier disruption that triggers sensitivity complaints, especially in Asian markets where skin reactivity benchmarks are stricter. We keep ethanol at or below 15% for most leave-on formats.

Propylene glycol (PG) at 5–10% is our second most-used enhancer in this category. It works through a different mechanism — disrupting the ordered lipid structure and acting as a co-solvent for poorly water-soluble actives. It also humects, which helps with the sensory finish. The clean beauty problem: PG has a perception issue. Some brand partners won’t touch it regardless of the safety data. We’ve switched projects to butylene glycol (BG) at equivalent concentrations for this reason alone, even though BG costs roughly 2.5× more per kilogram.

Oleic acid is interesting and underused. At 1–3% in an essence, it intercalates into the stratum corneum lipid bilayers and creates transient fluidization that can dramatically increase flux for lipophilic actives like retinol or ceramide precursors. The catch: it’s an oil. Getting it to stay in solution in a low-viscosity aqueous base requires either a co-solvent system or a very carefully selected emulsifier at sub-0.5% levels. We’ve had batches where it looked perfect at 500g lab scale and then separated within 72 hours at 50kg production. The shear profile during scale-up changes everything.

For vesicular delivery — liposomes, niosomes — the penetration enhancement data is genuinely good. One double-blind, vehicle-controlled clinical study (n=42, 8 weeks, twice-daily application) showed 34% greater transdermal flux for encapsulated hyaluronic acid fragments versus free HA in an equivalent toner base, measured by tape-stripping and TEWL reduction. What that study doesn’t tell you is the stability story. Liposome integrity at 40°C/75% RH over 12 weeks is where most suppliers’ data gets optimistic. We’ve seen encapsulation efficiency drop from 85% at T=0 to under 40% by week 10 in accelerated stability. That’s not a delivery system anymore — it’s just expensive HA.

See our detailed encapsulation technology documentation at Encapsulation Technology for how we approach vesicular system stability in production.

The pH Window: Where Most Projects Go Sideways #

Drop below pH 3.5 and you’re in regulatory grey territory in the EU. Most brands don’t realize this until we tell them. Under EU Cosmetics Regulation 1223/2009, products with pH below 3.0 may trigger classification as a borderline medicinal product depending on the active and the claim. We’ve had to reformulate two projects in the past 18 months because the brand’s marketing team had already written “clinical-strength AHA” copy before the regulatory review came back.

For penetration enhancement, pH matters because it directly controls the ionization state of your active. Glycolic acid at pH 3.5 has roughly 24% free acid fraction. At pH 4.0, that drops to about 9%. The free acid is what penetrates. So when a brand asks us to “keep it gentle” by raising pH to 4.5, they’re also asking us to cut efficacy by more than half. We explain this trade-off in every AHA brief. See our Acid Exfoliation Technology documentation for the full pH-efficacy curve data we use internally.

The preservative system is also pH-dependent in ways that catch brands off guard. Phenoxyethanol is effective across a wide range, but sodium benzoate — a common clean-label preservative — loses most of its antimicrobial activity above pH 4.5. We’ve seen this failure mode on production scale: a formula that passed challenge testing at pH 4.2 in the lab was reformulated to pH 4.8 at the brand’s request for sensory reasons, and gram-negative organisms appeared at week 8 of post-challenge testing. The formula had to be scrapped. That’s a 14-week delay and a full batch loss.

Premium vs. Mass-Market Specs: What You’re Actually Paying For #

This is where the conversation gets honest. The performance gap between a $0.80/unit toner and a $3.50/unit essence is real, but it’s not always where brands expect it.

The packaging line in that table is where brands consistently underestimate cost. Airless pump adds $0.40–$0.80 per unit at MOQ 3,000. Most indie brands can’t absorb that at launch. We usually recommend starting with a well-sealed glass dropper bottle with a nitrogen flush — it’s not as elegant as airless, but it protects oxidation-sensitive actives like vitamin C and retinol at roughly half the packaging cost.

The premium tier’s real differentiator isn’t the active concentration. It’s the pH control tolerance and the delivery system integrity over time. A transfersome system that’s still 80%+ intact at month 18 is genuinely different from a liposome system that’s degraded to 35%. Brands paying for premium should be asking their OEM for encapsulation integrity data at T=18, not just T=0.

Honestly, most brands underestimate how much the batch-to-batch pH variance matters at scale. A ±0.3 swing sounds small. In a formula with sodium benzoate as the primary preservative, that swing can mean the difference between a passing and failing microbial challenge.

Development Timeline: What to Expect #

We run toner and essence development on a 14–20 week timeline from brief to production-ready formula, depending on complexity. Here’s how that breaks down in practice:

Weeks 1–2 are brief intake and raw material sourcing confirmation. If you’re requesting a novel encapsulated active from a single-source supplier, add 3–4 weeks here. We’ve been burned by supplier lead times on specialty liposome systems — we now require a 6-month minimum stock commitment from suppliers before we put a vesicular system into a commercial formula.

Weeks 3–6 cover lab-scale prototype development. We typically run 3–5 formula iterations at 200–500g scale. pH optimization, enhancer concentration titration, sensory panel (internal, 8–12 evaluators). This is also where we run preliminary compatibility testing on the proposed packaging.

Weeks 7–10: stability initiation and challenge testing. We run ICH-aligned accelerated conditions — 40°C/75% RH and 25°C/60% RH simultaneously. Challenge testing per ISO 11930 runs in parallel. For ICH Stability Guidelines compliance, we need a minimum 6-month real-time data set before commercial launch recommendation.

Weeks 11–14: scale-up to pilot batch (typically 20–50kg). This is where things get interesting. Mixing order, shear rate, temperature profile during manufacturing — all of these can shift the formula behavior. We document every deviation from lab protocol.

Weeks 15–20: production batch, QC release, documentation package. For brands targeting EU or US markets, we prepare the full technical dossier aligned with EU Cosmetics Regulation 1223/2009 and FDA Cosmetics Guidelines simultaneously. For NMPA registration in China, the timeline extends — add 8–12 months for the registration pathway, which runs in parallel with commercial launch in other markets. See NMPA Cosmetic Regulation for current registration requirements.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask in every kickoff. Not because we’re being difficult — because the answers change the formula architecture completely.

A “5% niacinamide brightening toner” for the EU market, a Korean-style 7-layer essence routine, and a US clinical-brand treatment water are three completely different formulas even if the active is identical. The EU version needs a full safety assessment under Annex I of the regulation. The Korean-style essence needs a specific sensory profile — thin, fast-absorbing, no tackiness — that constrains your humectant and enhancer choices. The US clinical brand needs efficacy language that the formula can actually support.

For penetration enhancer selection specifically: tell us the active first, then the claim, then the market. In that order. If you come to us with packaging design before the formula is locked, we’ve learned to slow that conversation down. Packaging decisions made before stability data is in hand cause more project delays than any other single factor we see.

Budget transparency matters too. If the target ex-works cost is under $1.00/unit, we’ll tell you upfront which delivery systems are off the table. Encapsulation at that price point is not realistic. We’d rather have that conversation in week 1 than week 12.

Frequently Asked Questions #

Q: We want to put “5% niacinamide” on the front of pack — is that actually what’s doing the work, or is the delivery system more important?

A: At 5%, niacinamide is doing the work — the concentration is high enough that delivery optimization is secondary. Where delivery matters more is at 2–3%, where you need the enhancer system to compensate for the lower active load. We’d formulate your 5% version at pH 6.0–6.5 with BG at 5% as the primary enhancer and call it done.

Q: Can we combine AHA exfoliation and a peptide active in the same toner?

A: Short answer: it’s complicated. AHAs need pH 3.5–4.0 for meaningful exfoliation. Most peptides — especially signal peptides like palmitoyl tripeptide-1 — show degradation below pH 4.5 over a 12-week stability window. We’ve run this combination successfully at pH 4.0 with a specific peptide that’s acid-stable, but it required 6 weeks of additional stability work to confirm. Don’t assume it works until you have the data.

Q: How long does it take to get a formula ready for EU launch?

A: Minimum 20 weeks from brief to production-ready, assuming no raw material delays. Add 4–6 weeks for the safety assessment and responsible person documentation required under EU Cosmetics Regulation 1223/2009. If you’re targeting a Q4 launch, brief us no later than Q1.

Q: We’ve heard liposomes are the gold standard for delivery — should we always specify them?

A: Not always. Liposome integrity at 40°C/75% RH is the real question. We’ve seen encapsulation efficiency drop below 40% by week 10 in accelerated stability — at that point you’re paying a 3× raw material premium for a system that’s mostly degraded. For heat-sensitive markets or brands without airless packaging, we often recommend a well-optimized chemical enhancer system over a vesicular one. It’s less exciting in the marketing deck but more reliable in the bottle.

Q: What’s the minimum order quantity for a custom toner formula?

A: Our standard MOQ for a custom low-viscosity formula is 500kg per batch, which typically yields 3,000–5,000 units depending on fill volume. For premium formats with specialty actives, we sometimes run pilot batches at 200kg, but the unit cost increases by roughly 25–30% at that scale. We’re transparent about this in the quote stage.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.